Vesencumab

Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1) . Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer[1][2].

Product Specifications

CAS Number

[1205533-60-3]

Product Name Alternative

MNRP-1685A

UNSPSC

12352203

Target

Complement System; EGFR; p38 MAPK; PDGFR

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vesencumab.html

Purity

99.89

Solubility

10 mM in DMSO

Smiles

[Vesencumab]

Molecular Weight

(145.262 kDa)

References & Citations

[1]Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced? Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8. |[2]Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11 (21) :3362.